Propylene glycol
These manufacturers do not place this the same way.
scroll for all 10 products →
| Section | Wockhardt UK Ltd1g Solution | Flamingo Pharma (UK) Ltd250mg Capsules | Flamingo Pharma (UK) LtdAmoxicillin 250 mg/5 ml Powder for Oral Suspension Sugar Free | Brown & Burk UK Ltd500mg Capsules | Flamingo Pharma (UK) Ltd500mg Capsules | Sandoz Limited500mg Capsules | Aurobindo Pharma - Milpharm Ltd.500mg Capsules | Bowmed Ibisqus Limited500mg Solution | Brown & Burk UK LtdAmoxicillin Sugar Free 125 mg/ 5 ml Powder for Oral Suspension | GlaxoSmithKline UKAugmentin 125/31 Suspension |
|---|---|---|---|---|---|---|---|---|---|---|
| ContraindicatedThe label says it must not be used. | ||||||||||
| WarningThe label says it can be used, with care. | ||||||||||
| InteractionThe label says another medicine affects it. | ||||||||||
| PregnancyThe label gives advice for pregnancy or breastfeeding. | ||||||||||
| ExcipientThe label lists it as an ingredient, not a restriction. | Excipient | Excipient | Excipient |
- Excipient
534–550 of 550 characters
ate E218 Propyl Parahydroxybenzoate E216 Gelatin (TSE Free) Sodium lauryl sulphate Printing ink components: Absolute alcohol Isopropyl alcohol Shellac Black iron oxide Butyl alcohol Propylene glycol
- Excipient
0–233 of 233 characters
Capsule content: Capsule shell: Black printing ink: Magnesium stearate Cellulose, microcrystalline Yellow iron oxide (E 172) Titanium dioxide (E 171) Gelatin (containing sodium) Propylene Glycol Shellac Black iron oxide (E172)
- Excipient
Aurobindo Pharma - Milpharm Ltd.
364–380 of 452 characters
1) To 100% Gelatin Cap: Indigo Carmine (E132) Erythrosine (E127) Titanium Dioxide (E171) To 100% Gelatin Composition of Ink Shellac Dehydrated Alcohol Isopropyl Alcohol Butyl Alcohol Propylene Glycol Strong Ammonia Solution Potassium Hydroxide Black Iron Oxide (E172)
- Not in scanned sections
No match in sections 4.3, 4.4, 4.5, 4.6, 6.1 as read for this label. Not the same as the label being silent.
- §4.3 read
- §4.4 read
- §4.5 read
- §4.6 read
- §6.1 read